Evidence map›Paper›PMID 40791813›Full record

ArticleMolecular therapy. Oncology2025

DNA-demethylation by DAC induces

Marije A J de Rooij, Miranda H Meeuwsen, Anne K Wouters, Dennis F G Remst, Renate S Hagedoorn, Dirk M van der Steen, Els M E Verdegaal, Tassilo L A Wachsmann, J H Frederik Falkenburg, Mirjam H M Heemskerk

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Marije A J de RooijDepartment of Hematology, Leiden University Medical Center, Leiden 2333ZA, the Netherlands.
Miranda H MeeuwsenDepartment of Hematology, Leiden University Medical Center, Leiden 2333ZA, the Netherlands.
Anne K WoutersDepartment of Hematology, Leiden University Medical Center, Leiden 2333ZA, the Netherlands.
Dennis F G RemstDepartment of Hematology, Leiden University Medical Center, Leiden 2333ZA, the Netherlands.
Renate S HagedoornDepartment of Hematology, Leiden University Medical Center, Leiden 2333ZA, the Netherlands.
Dirk M van der SteenDepartment of Hematology, Leiden University Medical Center, Leiden 2333ZA, the Netherlands.
Els M E VerdegaalDepartment of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden 2333ZA, the Netherlands.
Tassilo L A WachsmannDepartment of Hematology, Leiden University Medical Center, Leiden 2333ZA, the Netherlands.
J H Frederik FalkenburgDepartment of Hematology, Leiden University Medical Center, Leiden 2333ZA, the Netherlands.
Mirjam H M HeemskerkDepartment of Hematology, Leiden University Medical Center, Leiden 2333ZA, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer testis antigens (CTAs) can be expressed in tumors, whereas expression is silenced in normal tissue except for the immune-privileged testis. This quasi-tumor-restricted expression makes CTAs attractive targets for T cell receptor (TCR) gene therapy. However, CTA-specific TCR gene therapy is only applicable for tumors with substantial and homogeneous CTA expression. To increase the number of patients eligible for CTA-specific TCR gene therapy, CTA expression can be upregulated with DNA-demethylating agents like 5-aza-2'-deoxycytidine (DAC). Here, we studied the effect of DAC on the recognition of a wide range of tumor cells by TCR-engineered T cells specific for the CTAs MAGE-A1, MAGE-A3/A6, or MAGE-A9. DAC treatment strongly increased

Indexed as

CD8+ T cellDACDNA-demethylationMAGEMT: Regular Issuesolid tumorsTCR

Identifiers

PMID40791813
PMCPMC12335964

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.